Erytech Pharma ADR
Earnings Details
4th Quarter December 2019
Tweet Share Watch

Erytech Pharma ADR (ERYP) Recent Earnings

Erytech Pharma ADR (ERYP) reported a 4th Quarter December 2019 loss of $1.21 per share on revenue of $0.0 million. The consensus estimate was a loss of $0.86 per share.

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

Reported Earnings
Earnings Whisper
Consensus Estimate
Reported Revenue
Revenue Estimate
Earnings Growth
Revenue Growth
Power Rating
Earnings Release